Multidimensional analysis of the pathological mechanisms of infantile hemangioma: metabolic reprogramming, immune remodeling, and programmed cell death

Infantile hemangioma (IH) is a common benign vascular tumor of infancy. Its self-limiting course, which progresses from proliferation to involution, involves aberrant angiogenesis, altered cell fate, and remodeling of the lesional microenvironment. Hypoxia/HIF-VEGF, PI3K/AKT, MAPK/ERK, and Notch signaling pathways contribute to vascular formation and cellular differentiation. During the proliferative phase, hemangioma endothelial cells (HemECs) undergo metabolic reprogramming characterized by enhanced glycolysis and altered amino acid metabolism, including pathways involving glutamine, arginine, glycine, and serine. Macrophages, mast cells, T cells, and their associated cytokines also shape a proangiogenic immune microenvironment. During the involuting phase, the transition of hemangioma stem cells (HemSCs) toward an adipogenic fate, together with changes in lesional cell composition, contributes to fibrofatty tissue remodeling. At the same time, the immune microenvironment undergoes stage-dependent remodeling, and processes related to programmed cell death, including apoptosis, pyroptosis, necroptosis, ferroptosis, and autophagy, change accordingly. However, the strength of evidence supporting these processes in IH varies. Current studies have identified specific links among metabolism, immunity, and cell death, but they have not established a fixed, sequential causal cascade; PANoptosis remains an unverified mechanistic hypothesis in IH. Although propranolol is the first-line treatment, variable treatment responses, rebound growth after treatment withdrawal, and refractory lesions remain clinical challenges. Focusing on the transition from proliferation to involution, this review integrates current evidence and potential mechanistic connections to inform research on spontaneous involution and the development of interventions tailored to specific disease stages and cell types.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-04
DOI
https://doi.org/10.3389/fphar.2026.1971229
Primary Topic
Vascular Malformations and Hemangiomas
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multidimensional analysis of the pathological mechanisms of infantile hemangioma: metabolic reprogramming, immune remodeling, and programmed cell death

Wenbo Li, Chong Liu, Ziming Wei, Houfan Zhu et al.
Frontiers in Pharmacology
Vascular Malformations and Hemangiomas
article

Multidimensional analysis of the pathological mechanisms of infantile hemangioma: metabolic reprogramming, immune remodeling, and programmed cell death

Wenbo Li, Chong Liu, Ziming Wei, Houfan Zhu, Yongjia Chen, Haizhou Pan, Haidi Hu, Yangjinyi An, Haoyi Liang
article en

Abstract

Infantile hemangioma (IH) is a common benign vascular tumor of infancy. Its self-limiting course, which progresses from proliferation to involution, involves aberrant angiogenesis, altered cell fate, and remodeling of the lesional microenvironment. Hypoxia/HIF-VEGF, PI3K/AKT, MAPK/ERK, and Notch signaling pathways contribute to vascular formation and cellular differentiation. During the proliferative phase, hemangioma endothelial cells (HemECs) undergo metabolic reprogramming characterized by enhanced glycolysis and altered amino acid metabolism, including pathways involving glutamine, arginine, glycine, and serine. Macrophages, mast cells, T cells, and their associated cytokines also shape a proangiogenic immune microenvironment. During the involuting phase, the transition of hemangioma stem cells (HemSCs) toward an adipogenic fate, together with changes in lesional cell composition, contributes to fibrofatty tissue remodeling. At the same time, the immune microenvironment undergoes stage-dependent remodeling, and processes related to programmed cell death, including apoptosis, pyroptosis, necroptosis, ferroptosis, and autophagy, change accordingly. However, the strength of evidence supporting these processes in IH varies. Current studies have identified specific links among metabolism, immunity, and cell death, but they have not established a fixed, sequential causal cascade; PANoptosis remains an unverified mechanistic hypothesis in IH. Although propranolol is the first-line treatment, variable treatment responses, rebound growth after treatment withdrawal, and refractory lesions remain clinical challenges. Focusing on the transition from proliferation to involution, this review integrates current evidence and potential mechanistic connections to inform research on spontaneous involution and the development of interventions tailored to specific disease stages and cell types.

Frontiers in PharmacologyVol. 17
Hainan Medical University (CN), China Medical University (CN)
Openalex Percentile: Top 11%
Vascular Malformations and Hemangiomas
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon